2021•Case Reports in Gastrointestinal MedicineOpen access

An Exceedingly Rare Case of Liraglutide-Induced Liver Injury

Swetha Parvataneni, Rajarajeshwari Ramachandran, Eric O. Then, Tyler Grantham, Vinaya V. Gaduputi

Open full text 6 citations

Abstract

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes mellitus. We are reporting the second case of liraglutide-induced liver injury, with complete resolution of liver injury after discontinuation of the drug.

Open-access reader

About this research paper

What this paper is about

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes mellitus. We are reporting the second case of liraglutide-induced liver injury, with complete resolution of liver injury after discontinuation of the drug.

Why it matters

OpenAlex reports 6 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes mellitus. We are reporting the second case of liraglutide-induced liver injury, with complete resolution of liver injury after discontinuation of the drug.

Key concepts: Liraglutide, Medicine, Discontinuation, Liver injury, Agonist, Diabetes mellitus, Type 2 Diabetes Mellitus, Glucagon-like peptide 1 receptor

Related papers

Back to paper searchBrowse research topicsOriginal source
An Exceedingly Rare Case of Liraglutide-Induced Liver Injury — Research Paper | ScholarLens